In non-small-cell lung cancer, ADAM9 (a member of the “a disintegrin and metalloprotease” family) expression was shown to be significantly greater in highly brain metastatic tumor cells compared to bone-metastatic or primary tumor cells, with higher invasive potential, increased adhesion capacities, and greater expression of integrin α3β1 [127]. The gene discussed is ADAM9; the disease is neoplasm.